Maternal pertussis vaccination has been introduced in several countries to protect infants from birth until routine infant vaccination takes place. This review assesses existing evidence on the effectiveness and safety of immunization in pregnancy. The search was finalized in April 2017 and was based on searches using several databases. The selection criteria included any experimental or observational study reporting on the immunogenicity, effectiveness or safety of vaccination with a pertussis-containing vaccine in pregnant women and their infants. Following de-duplication and exclusions, we identified 8395 studies, which were reduced to 46 for inclusion. The overall risk of bias was low, with the exception of some early studies and pharmacovigilance safety data. The evidence demonstrates efficient transplacental transfer of maternal antibodies in infants whose mothers were vaccinated with Tdap or Tdap/IPV in pregnancy, with good evidence that this protects against disease in young infants. Safety studies covering more than 150 000 women vaccinated mostly in the late second or third trimesters are generally consistent and provide reassurance of no significant increased risk of recognized maternal conditions or of adverse events (including congenital anomalies) in infants born to vaccinated women. The clinical significance of reduced seroconversion to pertussis following routine immunization is not yet clear, but no increased risk of pertussis in infants whose mothers were vaccinated in pregnancy was found following primary immunizations in North American and English studies. Most post-booster studies suggest that any blunting effect is shortlived and that longer-term protection in infants from active immunization is not compromised.
Pertussis remains an under-recognized disease, especially in teenagers and adults, despite new laboratory methods in some countries, such as serological and other antibody tests, which have contributed to improved ascertainment [3] . However, direct comparison between countries remains difficult due to differences in the sensitivity of surveillance systems, differing schedules and the different pertussis vaccines in use, as well as potential differences in the local disease burden and transmission patterns.
Clinical trials during the 1990s suggested that new aP vaccines were less reactogenic and conferred comparable effectiveness, depending on the wP-and aP-containing vaccine used [4] . As a result, high-income countries started replacing combined DTwP vaccines with combination aP vaccines from the 1990s, primarily due to the reduced reactogenicity of the aP component [5] . More recent studies indicated that aP vaccines may be less effective than the highest efficacy wP vaccines, with more rapid waning of protection following the primary infant series [4, 6] , and in primate studies aP vaccine failed to prevent infection and transmission [7] . A number of developed countries with long-standing vaccination programmes also reported a resurgence of pertussis despite sustained high vaccine coverage [8] [9] [10] [11] [12] [13] . As a result, the World Health Organization (WHO) recommended that low-income countries using wP-containing vaccines should only consider switching to aP-containing vaccines if additional booster or maternal immunization could be assured and sustained [6] . This also led to a growing international debate on strategies to optimize pertussis control and maximize protection in infants, particularly infants too young to be vaccinated when they are at high risk of severe disease. The WHO considered vaccination of pregnant women to be the most cost-effective additional strategy to protect infants during this susceptible period, and whilst the 'cocooning' strategy has been adopted in some countries, it is difficult to achieve high uptake and evidence of its effectiveness is inconsistent [6] .
In 2011, following an increase in pertussis, the USA became the first country to advise that pertussis vaccine be administered to pregnant women in the third trimester [14] , and in October 2012 this advice was updated to recommend vaccination in every pregnancy [15] . Argentina introduced universal free maternal pertussis vaccination in February 2012 from 20 weeks of pregnancy [16] . In the UK, a temporary maternal vaccination programme was introduced in October 2012 in response to an outbreak [17] . Other countries, including Australia, Belgium and Spain, have since introduced maternal pertussis vaccination programmes. At the time of programme introduction, evidence of effectiveness was largely extrapolated from immunogenicity studies. Antenatal maternal immunization programmes for other vaccine-preventable diseases, such as tetanus, are well established and effective in reducing neonatal mortality [18] . Maternal influenza vaccination protects both infants and pregnant women against severe disease and death, and with pregnant women being identified by the WHO in 2012 as the highest priority group for seasonal influenza vaccination, this programme is now routine in a number of countries [19] .
Studies of antibody responses in women of child-bearing age suggest that this is maximal for pertussis-containing vaccines approximately 14 days after immunization [20] . All subclasses of immunoglobulin class G (IgG) are transferred from mother to infant across the placenta, primarily during the third trimester of pregnancy [21] . Transplacental pertussis IgG antibody transfer has been demonstrated, with the concentrations in newborns [22, 23] or cord serum samples [22, 24, 25] being reflective of those in the mother. Maternal antibodies are thought to have a half-life of approximately 6 weeks and so, if boosted to sufficiently high levels, are likely to provide time-limited, passive protection for newborn infants prior to their first childhood immunizations [23, 26] , although there is no clear immunological correlate of protection for pertussis
The early safety data for aP-containing vaccines during pregnancy were largely derived from pregnancy registries; thus population-based safety evaluation has been a priority. Enhanced reactogenicity of aP pertussis vaccines has been described with increasing numbers of doses in infants and young children and is associated with more pronounced local side-effects for the tetanus component [27] , but data following maternal antenatal vaccination are required.
There has been concern that maternally derived antibodies could interfere significantly with the infant's own response to pertussis vaccine antigens and other antigens in the primary infant series. The clinical relevance of any observed inhibitory effect (blunting), if any, was difficult to ascertain, however, prior to the implementation of national programmes due to the lack of an agreed correlate of protection for pertussis. Research suggested that pre-existing maternal pertussis antibodies did not affect the PT antibody response to DTaP in infants, although modest inhibitory effects were seen with other pertussis antibodies [28] . Blunting has, however, been demonstrated for other vaccines, such as measles [29] , and with pertussis-containing vaccines administered at birth [28, 30, 31] . Any blunting effect may differ depending on the infant immunization schedule in place and whether infants receive wP or aP vaccines for their primary series, as suggested in the study by Englund et al. [28] .
This review aimed to assess existing evidence for the effectiveness and safety of immunization in pregnancy (in any trimester) in preventing pertussis disease in infants too young to be protected by routine primary vaccinations.
METHODS
We included any primary experimental or observational study, or secondary study reporting on the effectiveness, immunogenicity or safety of antenatal vaccination with a pertussis-containing vaccine.
We included studies that reported on: pregnant women of all ages and gestations of pregnancy, with any pregnancy (single, multiple, complicated or uncomplicated) or parity, and their infants. We excluded animal studies.
The review included studies with any pertussis-containing vaccine (aP or wP) administered at any stage of pregnancy, as compared with no vaccination, sham or placebo vaccination. In most countries, the vaccines used in the maternal programmes are licensed Tdap vaccines, e.g. Adacel or Boostrix in the USA (ACIP 2011, https://www.cdc.gov/ mmwr/preview/mmwrhtml/mm6037a3.htm?s_cid= mm6037a3_w). In the UK dTaP-IPV vaccine (Repevax and Boostrix-IPV) is used as the licensed aP booster vaccine for use in adults and adolescents (PHE 2016, https://www.gov. uk/government/publications/pertussis-the-green-bookchapter-24).
Primary outcome measures were:
(1) Evidence of protection against pertussis disease in infants following pertussis immunization in pregnancy, where pertussis was specified as the primary diagnosis or a major contributing factor. (2) Evidence of the safety of vaccination in pregnancy, as demonstrated by consideration of major adverse events in the mother and/or in the foetus/newborn/ infant. We excluded any study that considered only minor (self-limiting) adverse events.
Secondary outcome measures were:
(1) Antibody response in the mother following pertussis vaccination in pregnancy. (2) Transplacental transfer of antibody as evidenced by cord, foetal or infant blood titres of maternally derived antibody to any vaccine component at birth or prior to the first primary vaccination. [32] .
In addition, snowballing techniques such as reference and citation tracking were carried out for all included papers. We merged the results using reference management software (Mendeley).
Data collection and analysis
Pairs of authors were randomly allocated references to review the titles and abstracts of all selected citations and obtain full-text articles when they appeared to meet the eligibility criteria, or when there was insufficient information to assess eligibility. Each author assessed the eligibility of the studies independently and we resolved any discordant assessments by discussion. When full text was obtained reasons for exclusions were assigned as inappropriate study type based on the intervention, population or outcome (see Fig. 1 ). We used Google Translate to assess the eligibility of papers in languages other than English and did not need to translate any full-length papers.
Three pairs of review authors were then randomly allocated selected references. One of each pair of review authors independently extracted data on study characteristics, participant characteristics and specifics of the intervention from the manuscript using pre-tested data extraction forms. The second author in the pair independently checked this for accuracy.
We assessed the risk of bias based on the seven domains of the adapted Cochrane risk of bias tool [33] . One review author assessed bias, a second author in the pair verified and one author (NA) collated whilst checking for consistency. For each domain we used categories of high risk, intermediate risk, low risk and not applicable. Not applicable was used when a domain was not relevant, which usually applied to random sequence generation, allocation concealment and blinding of participants for observational studies. To make the tool more relevant to the multifactorial outcomes we were assessing, we divided the 'other' category into three and used it to assess the implications of the risk of bias in the other domains, as well as other biases such as confounding of the outcomes relating to safety, immunogenicity and effectiveness/efficacy. The justification for each category was documented. We assessed obvious heterogeneity at face value by comparing populations, settings, interventions and outcomes.
We could not perform a meta-analysis of studies as the intervention, design and end points were dissimilar. We therefore summarized the results of different studies, including the quality of the available evidence for each outcome, but have not produced pooled estimates. Evidence from randomized controlled trials (RCTs) was analysed separately from observational evidence.
RESULTS
We identified 7269 records through database searching from the 1940s to end March 2014, which were reduced to 7184 records after de-duplication, while a further 6947 records were excluded on initial review of the titles and abstracts (Fig. 1) . Of the 237 publications identified for screening, 7 could not be obtained. Twenty-three additional records were found by snowballing. These 253 full-text articles were reduced to 11 for inclusion in the review. In the later searches covering the period February 2014 to April 2017, 1038 unique new publications were identified. On review of the title and abstract, a further 987 were excluded and 51 full-text articles were assessed for eligibility, of which 35 were included in the final review.
Therefore, of the 304 full articles screened, 46 were included in the review. A summary of the exclusion categories is shown in Fig. 1 and details of the excluded studies are available on request. The 46 included studies were divided into categories according to the specified primary and secondary outcomes and further categorized according to whether wP or aP vaccines were used. Funding sources were not always clear, but in 2 studies the only sources mentioned were pharmaceutical companies, while 6 had partial funding or laboratory support from pharmaceutical companies, 14 had no funding source listed and 24 were funded by non-pharmaceutical sources.
Risk of bias in included studies
The risk of bias in the included studies is summarized in Fig. 2 (rationale available in supplementary materials). Most of the studies were non-randomized and so were not assessed for random sequence generation, allocation concealment or for blinding of participants and personnel, but it should be recognized that such studies are at risk of selection bias where women choosing not to be vaccinated are inherently different in a way that may also affect the outcomes. This is most likely to impact on safety outcomes, where potential confounding variables could be concomitant drug treatment, medical and obstetric history, smoking and body mass index. It should also be noted that a number of the observational studies had restrictive inclusion criteria, potentially impacting on the external validity of their findings. For the randomized studies, details of how the random sequence was generated and concealed as well as blinding were generally missing. It is recognized that a lack of appropriate randomization might result in selection bias, although little additional risk of bias for immunogenicity/safety outcomes was identified. For non-randomized studies it is clear that study participants and personnel will know the vaccine given/received, but it is not necessary for those assessing the end points to know the vaccination status. Although this was rarely documented, this is unlikely to introduce bias for objective measures such as immunogenicity or adverse events, but may bias more subjective assessments such as clinical assessment or referral for testing. Attrition bias (incomplete outcome data) was unlikely in most studies, but in four instances it was deemed to be high [34] [35] [36] [37] . Most studies reported on all of the outcomes described in the methods, making reporting bias unlikely, with one exception [34] . Bias for safety, immunogenicity and effectiveness outcomes are summarized further within each section describing the results.
The risk of bias due to industry funding was judged to be low in the two studies where this was the only source of funding identified; in one the company had no input into the study design, analysis or writing [38] , and in the other the grant was unrestricted and the company's main involvement was blinded laboratory analysis [39] . In five of the the six studies with partial funding this was done indirectly through university-allocated post funding or laboratory support from pharmaceutical companies [40] [41] [42] [43] [44] , while in the other (a safety study) it was done by funding one of two study locations [45] . In this last study the authors are nonpharmaceutical, but it is not made clear whether the company had any influence on the study analysis and publication, so this is a potential source of bias in this study.
Protection against pertussis disease in infants
There were seven studies (one with wP and six using aP) that estimated the effectiveness of maternal pertussis vaccination in protecting young infants against pertussis disease before infant vaccination (Table 1 ). Cohen and Scadron [46] used a wP vaccine in an intervention study and found no pertussis cases by 5 months of age (0 cases/100, from 8 known exposures) and 2 cases between the ages of 6 and 11 months (2 cases/100, exposures not provided) in children with vaccinated mothers [46] . In children born to unvaccinated mothers, there were 3 cases to 5 months of age (3 cases/100, from 6 known exposures) and 2 cases between 6 and 11 months (2 cases/100, exposures not provided).
Two recent observational studies in England [47, 48] assessed the national maternal aP-vaccination programme, recommended from 28 weeks' gestation, with vaccine effectiveness being estimated using the screening method. One unmatched case-control study [49] has also been published based on data from England. Three studies in the USA were retrospective cohort studies of babies born to women immunized with aP-containing vaccine which was recommended at 27-36 weeks' gestation [50] [51] [52] . There was consistency in the level of VE estimated from all of these studies at 90-93 % against disease and 95 % against death from pertussis [48, 52] in infants <2 months (or <8 weeks) of age. A comparison of the effectiveness of maternal dT5aP-IPV and dT3aP-IPV vaccines used in England found no statistically significant difference between the two vaccines [48] . Winter found that vaccination in pregnancy reduced the risk of hospitalization from pertussis and that babies hospitalized with pertussis had a shorter duration of stay if their mother had been vaccinated [50] . Tdap vaccination during 27-36 weeks' gestation was 85 % more effective than postpartum vaccination at preventing pertussis in infants <8 weeks of age [51] .
The risk of bias for effectiveness was intermediate in all of the studies except for that by Cohen and Scadron [46] , where it was judged to be high due to the lack of clarity concerning the selection of unimmunized mothers (Fig. 2) . The studies in England allowed for the most likely confounder of time period, as well as maternal age, whereas the US cohort studies adjusted for additional variables, such as ethnicity and parity, but not all possible confounders. A low risk of bias could not be assigned due to the lack of a randomized study, but the consistency of results across these studies and populations provides fairly robust evidence of protection.
Pertussis vaccination safety for mothers and infants during pregnancy
Three studies which used wP vaccine in pregnant women (totalling around 350 women) reported on safety with no detailed methodology and minimal details on participants [34, 46, 53] . These studies reported no premature births or postpartum complications ascribed to vaccination and babies were described as doing equally well in those born to both immunized and unimmunized mothers.
Sixteen studies of aP vaccination in pregnancy [36, 37, 41, 42, 44, 45, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] looked at vaccine safety in a total of nearly 150 000 vaccinated women ( Table 2 ). The sample sizes ranged from 33 to over 53 000 and the studies assessed the safety of different aP-containing combination vaccines used in programmes globally. These included Tdap and Tdap/IPV vaccines with three or five pertussis components, with the timing of vaccination ranging from 19 to 38 weeks where specified. One study also included women immunized in the first and second trimesters, but the analysis could not be broken down by trimester [37] and results were only analysed by 0-14 weeks' or 27-36 weeks' gestation in one study (specifically on microencephaly), with no increased risk identified [62] . Four studies undertook infant follow-up beyond the neonatal period. Munoz et al undertook a small case-control study that reported no differences in infant growth or development at 13 months [63] . Shakib et al. retrospectively compared recorded health encounters and diagnoses by 12 months of age in infants born to vaccinated and unvaccinated mothers [58] . They had similar rates of healthcare utilization (62 % with vaccinated mothers vs 61 % with unvaccinated mothers) and no significant difference in the proportion of these infants diagnosed with complex chronic health conditions (3.6 vs 10.4 % with unvaccinated mothers, P=0.54). A prospective observational study in New Zealand undertook follow-up of infants born to immunized mothers with infant outcomes collected from maternal reporting and routine health records to 12 months of age [59] . Analysis was undertaken on 408 infants followed to at least 6 months of age: no increased risk of congenital anomaly was found compared to background rates in New Zealand and infant weights were normally distributed at the 5-month check. In a prospective controlled cohort study followed up infants to 15-16 months of age; this reported no statistically significant difference in the proportion of infants hospitalized during the study period between maternally vaccinated and unvaccinated study groups (10.9 vs 12.5 % hospitalized, respectively) [44] . A neurological development test undertaken as part of this study found that the infants in the vaccine group were significantly better developed for 2 of 11 items in comparison with infants from the control group; as these skills were not expected to be present among all infants of that age, the results were not presented by the authors.
The risk of bias for safety was judged to be low in 3 studies, intermediate in 11 studies and high in 5 studies (Fig. 2) . The high risk was found in the older studies, such as Cohen and Scadron [34, 46] and Mishulow et al. [53] , where details were limited, and in the pharmacovigilance studies of Moro et al. [36] and Zheteyeva et al. [37] . The low risk applied to two clinical trials [60, 63] and Walls et al. [59] , where there was good follow-up. It is, however, acknowledged that the details of randomization were often lacking, perhaps resulting in selection bias.
Secondary outcome: maternal antibody response following pertussis vaccination during pregnancy Five older studies used different whole-cell pertussis vaccines in pregnant women and applied different tests to study their response. Four of these studies demonstrated higher responses in vaccinated compared to unvaccinated women [34, 46, 53, 64] (Table 3) , and whilst Lichty et al. did not find a significant increase in phagocytic activity in women following immunization [35] , they did observe that this was higher in babies born to immunized women and to women with a history of pertussis. Eleven studies using different aP-containing vaccines consistently showed that IgG antibodies against the pertussis antigens considered were significantly higher at delivery in vaccinated women when compared to unvaccinated pregnant women, women immunized with a vaccine that did not contain aP or women immunized postpartum [39-41, 60, 63, 65-70] . Pertussis-specific IgG levels decreased significantly 9 to 15 months after delivery in two studies [69, 70] , but were still higher than those of unimmunized women. Vaccine specific CMI responses were boosted to a lesser extent in pregnant than in non-pregnant women, but this stimulation was transient and only observed at 1 month and not at 1 year after vaccination [69] .
Secondary outcome: transplacental transfer of antibodies Five studies of wP vaccine administration in pregnant women found evidence of pertussis responses in their infants that were greater than those in infants born to women who had not been vaccinated [34, 35, 46, 64] , although Greenberg et al. suggested that the difference they detected was too low to make any inferences and that their vaccine schedule required adjustments [71] .
We have taken studies using cord blood samples to be indicative of antibody levels in the newborn. Statistically higher levels of aP-vaccine antibodies have consistently been found in 14 studies of babies born to vaccinated pregnant women compared to those born to women who were not vaccinated in pregnancy [39, 41, 42, 60, 63, [65] [66] [67] [72] [73] [74] , to be in line with suggested levels of protection [68, 75] or to induce higher antibody avidity [76] . In addition, Eberhardt et al. [77] and Kent et al. [38] specifically studied preterm infants and found antibody levels consistent with putative levels of protection and higher antibody levels, respectively, at 2 months in infants following maternal vaccination, but these were lower in the maternally vaccinated cohort after primary vaccination [38] .
Whilst the difference did not reach statistical significance, Healy et al. identified that placental transport of pertussis antibodies was better in women immunized during pregnancy than women immunized a short time before, and that pertussis-specific IgG concentrations waned rapidly [40] . Despite the waning of maternal pertussis antibodies in infants during the first 2 months of life, the levels remained elevated in babies born to mothers vaccinated in pregnancy until the age that routine infant vaccination began, resulting in a closure of the susceptibility gap for the youngest infants [39, 41, 42, 60, 67, 68, 72, 74] , including those born prematurely [38] ; this is consistent with evidence of the effectiveness of maternal pertussis vaccination in protecting young infants.
Secondary outcome: the effect of the timing of maternal vaccination on the transplacental transfer of maternal antibodies or on the risk of disease in the infant We found seven studies reporting on the timing of maternal aP vaccination responses and infant antibody levels, but in one the numbers were too small to identify a significant difference [72] . Healy et al.'s findings suggested that whilst there was highly efficient placental transport of maternal antibodies in women immunized up to 2 years prior to delivery, pertussis antigen-specific IgG concentrations in their newborns were unlikely to be high enough to passively protect them through 2 or 3 months of age. More infants whose mothers were immunized in pregnancy had nominally adequate PT levels at birth, but only three women in their study were immunized after 20 weeks' gestation [40] . Abu Raya et al. [73] reported higher anti-PT and FHA antibody concentrations following immunization at 27-30 weeks compared to beyond 31 weeks, with similarly significantly higher antibody avidity in cord sera of newborns with mothers vaccinated at 27-30 weeks' gestation compared to those with mothers vaccinated after 30 weeks [76] . Ladhani et al. [74] found that the timing of antenatal pertussis immunization in the third trimester did not affect infant antibody concentrations at 2 months in the infant. Naidu et al. [78] found that the cord blood levels of antipertussis antibodies were higher in babies whose mothers had been vaccinated at 28-32 weeks as compared to those whose mothers were vaccinated at 33-36 weeks.
Only Eberhardt et al. [75] reported on earlier vaccination and found higher infant anti-PT and -FHA antibody concentrations following immunization at 13-25 weeks rather than from 26 weeks, and they later published a prospective observational study that found higher PT and FHA antibodies in preterm babies born to women vaccinated in the second compared to the third trimester [77] . Eberhardt et al.'s overall findings were not consistent with those in Winter et al.'s study, which reported that infants whose mothers were vaccinated during the second trimester were significantly more likely to have pertussis by age <8 weeks or 12 weeks than those whose mothers were vaccinated at 27-36 weeks' gestation, when controlling for the age of the mother, number of prior births and preterm birth [51] . There were, however, some limitations to Winter et al.'s observational study, as only 14 % of women received Tdap vaccine before 27 weeks' gestation; this was outside the routine recommendations and therefore these women may have differed from women who were vaccinated within the recommendations. The distribution of the timing of vaccination was not presented and it is not clear how many women received vaccine in the second trimester but close to the national recommendation of 27 weeks.
Secondary outcome: blunting Concern over maternally derived antibodies interfering with the infant response resulted in several studies evaluating this blunting effect. Our review identified 10 studies ( Table 4 ) that had assessed laboratory markers of pertussis responses following primary schedule in infants following maternal vaccination with different Tdap or Tdap/IPV vaccines (three-and five-component pertussis vaccines) conducted in a number of settings using different infant schedules [38, 39, 41-44, 60, 63, 74, 79] . In most of the studies, evidence of lower responses to one or more pertussis antigen were observed amongst infants born to vaccinated mothers following the completion of their primary schedule when compared to infants whose mothers had not been vaccinated. However, the antibody responses to specific pertussis antigens differed between studies, with some increases reported inconsistently. In one study, differences based on antibody avidity were reported to be non-significant after the primary course [79] . Premature infants had significantly higher GMCs of IgG to pertussis antigens, tetanus and diphtheria toxoid (DT) before primary vaccination if their mother had been vaccinated, although FHA and DT were significantly lower after completion of the primary course [38] .
Importantly, no evidence of a clinically significant blunting effect was found in England and the USA based on studies of infant disease in the first year of life after maternal vaccination and primary infant doses [48, 52] .
In four studies, lowered response to pertussis components in maternally vaccinated infants was no longer significant following the booster dose in the second year of life [39, 43, 44, 63] , suggesting that any blunting effect may be short-lived and that longer-term protection conferred to infants from active immunization is not compromised. Cabore et al. [79] found that only avidity to PT was significantly lower in the maternally vaccinated group after booster vaccination at 15 months [79] .
In five studies other routine antigens were assessed [41-43, 63, 74] , with some evidence indicating an enhancement of the response to tetanus and tetanus-conjugated vaccines and a decline in diphtheria and CRM-conjugated vaccine responses. However, similar proportions of infants attained levels consistent with protection for diphtheria and group C meningococcus [74] . Maertens also reported significantly lower anti-TT antibody titres in infants whose mothers were Tdap-vaccinated, rather than TT-vaccinated, following the booster dose [43] . Whilst an effect of maternal TdaP on [74, 80] has been reported, this effect disappeared after a booster dose at the age of 12 months, except for serotypes 1 and 4 [80] , and the proportion of children reaching the protective threshold for all pneumococcal serotypes was the same in both the exposed and unexposed cohorts.
The risk of bias for the various immunogenicity outcomes was deemed to be low for 18 studies, intermediate for 10 studies and only high for [34] due to selective reporting and outcome data (Fig. 2) . This generally lower risk of bias was because of the more objective nature of immunogenicity assessment, but it was still deemed to be intermediate in studies where the groups differed (e.g. according to the time in pregnancy of the blood test, the period of study, or the time when laboratory analysis performed).
DISCUSSION AND CONCLUSIONS
Whilst the safety and efficacy of pertussis vaccines in pregnancy were first assessed using wP vaccines in the 1940s, it was not until 2011 that aP pertussis-containing vaccines were first recommended in pregnancy. Universal maternal vaccination programmes have been introduced in a number of countries following reported disease incidence increases and relatively high morbidity and mortality in young unimmunized infants, and a lack of convincing evidence on the effectiveness of cocooning strategies. These recommendations were informed by national epidemiology and available immunogenicity and safety data. There was also evidence of very low levels of pertussis antibodies as a baseline even in young women from countries with an adolescent programme [40] . However, the lack of an established correlate of protection for pertussis meant that the efficacy of this strategy in preventing infant disease could not be extrapolated directly from these data. The implementation of maternal pertussis vaccination programmes in some middle-and high-income countries has provided opportunities to further assess the safety of the programme at a population level and provide the first evidence of its effectiveness in preventing infant disease.
In this review, a total of 46 relevant studies with around 345 000 participants in total were included. These studies considered women who received either acellular or wholecell pertussis vaccine during pregnancy. [39-42, 57, 60, 63, 67, 69, 73, 74, 76] . England was the first country to demonstrate high effectiveness (~90 %) of maternal immunization with a fivecomponent DTaP-IPV vaccine in preventing disease in young infants, using both the screening and case-control methods [47, 49] . Similar overall vaccine effectiveness was found 3 years post-implementation in England, with a lower point estimate of VE in infants with mothers vaccinated with a three-component compared to a five-component vaccine that did not reach statistical significance [48] . One study in the USA found remarkably similar VE [52] and others concluded that Tdap vaccination in pregnancy was more effective than postpartum vaccination at preventing pertussis in young infants [51] , lowered the risk of hospitalization and intensive care unit admission and was associated with shorter hospital stays [50] .
It would clearly be desirable to demonstrate effectiveness against infant disease under more maternal programmes using different schedules and wP in the infant schedule and/ or establish a correlate of protection. The rapid waning of antibody levels in women who were vaccinated in pregnancy and the greater efficiency of transplacental antibody transfer after around 34 weeks' gestation informed the decision in most countries to offer maternal vaccination from 28 weeks [40] . More recent studies found optimal neonatal pertussis antibody concentrations were elicited following maternal vaccination between 13 and 33 weeks' gestation [75, 77] , although the data on vaccination in the second trimester are currently limited and inconsistent, with Winter et al. finding a higher risk of pertussis in infants whose mothers were vaccinated in the second compared to the third trimester [51] . However, studies in the third trimester found higher maternal and infant pertussis antibody levels (consistently pertussis toxin) and avidity in infants when vaccination was earlier rather than later in the third trimester [73, 76, 78] , or that there was no significant difference [74] . There is currently a paucity of data on cell-mediated immunity following maternal immunization and such data could further our understanding of the significance of waning antibody levels. The recommendation in the UK (currently from week 16 of pregnancy) changed following evidence of a potential improvement in neonatal antibody levels [75] and in recognition that earlier vaccination in pregnancy would provide more opportunities for women to be vaccinated and offer protection to infants born at earlier gestation [77, 81] . Vaccine uptake in the UK has since improved [82] and estimates of the effectiveness of earlier vaccination in pregnancy against infant disease are underway.
Despite the success of maternal immunization programmes in countries such as the UK, there are still some gaps in our understanding of this strategy. In particular, current evidence has shown lower pertussis responses to primary infant vaccination, with a lack of consistency in the response to specific antigens (notably PT and FHA) in infants born to vaccinated mothers. This could be due to other factors affecting the likelihood of pertussis exposure or simply reflect the difficulty of interpreting pertussis Ig responses, as these may not directly correlate with levels of protection. Further, there is currently no evidence of increased risk of pertussis disease in infants with vaccinated mothers following primary vaccinations in the first year of life.
For many countries with a pertussis booster scheduled in the second year of life, any clinically significant blunting will likely be mitigated through the booster dose. For countries only offering boosting at pre-school, the relevance of blunting is particularly pertinent and requires close monitoring. Determination of a laboratory correlate of protection has been an ongoing priority, but we now have the opportunity to make progress in this area by assessing the levels of antibodies in cord blood and the risk of infant disease. Longer-term follow-up is required to assess whether maternal vaccination leads to more rapid waning after the completion of primary and early booster schedules and any effect from different maternal and primary schedules and repeated maternal vaccination. Evidence of interference with Tdap and PCV vaccines using the diphtheria-derived CRM carrier protein and the enhancement of the response to tetanus vaccine and vaccines using tetanus toxoid carrier protein are important findings that are likely to help inform future vaccine development and potential changes to the vaccine programme to minimize any blunting effect. It is also important to generate robust data on any lasting blunting effect post-booster.
Safety studies covering more than 150 000 women vaccinated mostly in the late second or third trimesters are generally consistent and provide reassuring evidence of no significant increased risk of recognized maternal conditions, including pregnancy outcome, or of adverse events (including congenital anomalies) in infants born to vaccinated women. The identification of a small but statistically significant risk of chorioamnionitis from one published safety study may benefit from further specific study as current evidence is not convincing and there is no clear biological plausibility for such an association or identified increased risk for associated outcomes. Other safety studies published at the time of the review did not replicate this finding. Two further studies that found a small increased relative risk of chorioamnionitis: one was conducted by Laytonet al. [82] . Another consideration is that the existing safety data, with limited exceptions [44, 58, 59] , are largely based on assessment covering the period during pregnancy and up to delivery. Further studies with longer follow-up periods would provide additional reassurance.
Biases in the review process may have occurred in the selection of included studies and by the review not being blinded to the study authors. The included studies only included those that adhered to our search criteria. The review authors were not blinded to study authorship or journal of publication, allowing the potential for bias during study selection and data extraction. The use of predefined criteria for study inclusion and rules for data extraction helped to minimize this potential [85] . When the authors of this review were co-authors in an included study, the potential for bias was minimized by ensuring that the criteria for study inclusion were checked by a different review author.
Current evidence supports the effectiveness of maternal pertussis immunization to protect from birth in those settings where there is a significant burden of pertussis disease in young infants despite high coverage of the routine vaccination programme. Good epidemiological data are therefore also key prior to the introduction of such programmes. Reassuring data on the safety of vaccination in pregnancy for mother and infant at birth are available in a range of settings. Current recommendations around maternal vaccination indicate that vaccination should be offered to women in every pregnancy. However, there remains a need for more data on the need to repeat vaccination in every pregnancy to ensure effectiveness, optimal timing for vaccination in pregnancy and further assurance on safety with longer-term follow-up of infants and larger studies that include pregnancy outcomes not restricted to those with live birth. In addition, there is an absence of data for maternal vaccination in settings where wP is used in the primary infant schedule.
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